tuneTypical Dose
100 mg daily of Aflapin or 169.33 mg twice daily of Boswellin in osteoarthritis trials
Botanical
Boswellia serrata
Boswellia serrata
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Some pain relief can appear within days in fast-acting extracts, but fuller osteoarthritis assessment usually takes several weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Boswellia has its best human evidence in knee osteoarthritis, where some proprietary extracts can reduce pain and improve function, but the data are product specific and not a license for broad inflammation claims.
Boswellia is often sold as a natural anti-inflammatory for joints, recovery, and general inflammatory health. The strongest human evidence is narrower than that. The best-supported use is knee osteoarthritis, where several randomized trials of proprietary extracts report improvements in pain and function. That makes Boswellia a plausible option for symptomatic osteoarthritis support, but not a general proof-of-concept that any frankincense product will meaningfully suppress systemic inflammation.
Boswellia extracts are usually framed around boswellic acids, including AKBA, with putative effects on inflammatory signaling such as 5-lipoxygenase pathways. The mechanistic story is plausible, but the useful clinical evidence is still mainly symptom reduction in osteoarthritis rather than validated broad anti-inflammatory disease modification.
Article
Boswellia serrata
Boswellia is one of the better joint-support botanicals, but the honest evidence story is narrower than supplement marketing suggests.
Most human data focus on knee osteoarthritis, not on broad inflammation, athletic recovery, or autoimmune disease. Within that osteoarthritis literature, the results are often positive, but they come from proprietary extracts with different boswellic-acid profiles and different study designs. So Boswellia deserves cautious optimism, not sweeping claims.
Where the evidence is strongest
A 2024 systematic review and meta-analysis is the best current overview for knee osteoarthritis. The pooled analysis was weakened by substantial heterogeneity and did not show a significant overall effect across all Boswellia studies, but placebo-based subgroup analyses were more favorable and supported a real symptom-relief signal.1
That is an important pattern. It suggests there is probably something real here, but it is not clean enough to treat Boswellia as a uniformly validated class of products.
A 2023 placebo-controlled trial of Aflapin, also known as AprèsFlex, is one of the stronger positive RCTs. In 70 adults with knee osteoarthritis, 100 mg daily for 30 days improved VAS, Lequesne, and WOMAC scores, with pain-score improvement reported as early as day 5.2
A longer 2019 placebo-controlled trial using Boswellin also supports a symptom benefit. In that study, 48 adults with knee osteoarthritis took 169.33 mg twice daily for 120 days and showed improvements in pain, stiffness, function, walking ability, hs-CRP, and some radiographic measures compared with placebo.3
What Boswellia is actually good for
The most defensible use case is adjunctive relief of knee osteoarthritis symptoms, especially when someone wants a non-NSAID option or cannot tolerate regular NSAID exposure.
The least defensible use cases are vague whole-body inflammation claims, autoimmune-disease claims, and assuming that any Boswellia capsule with no meaningful standardization will reproduce the better trials.
Dosing
The best human evidence is tied to specific extracts, not to a single universal Boswellia dose.
Reasonable evidence-aligned examples include:
- 100 mg daily of Aflapin or AprèsFlex for 30 days
- 169.33 mg twice daily of Boswellin for 120 days
Those protocols should not be treated as proof that all Boswellia supplements are interchangeable. Standardization and extract identity matter.
Safety
Boswellia appears generally well tolerated in clinical trials, with GI upset as the main practical side effect. The human data do not show a major toxicity pattern at usual osteoarthritis-study doses.
Still, it is a resin extract rather than a dietary essential. Pregnancy, lactation, active ulcer disease, and concurrent use with multiple GI-irritating supplements should be handled conservatively. Blood-thinning concerns are usually theoretical rather than strongly proven, but caution is still reasonable around surgery or when stacking with anticoagulant strategies.
Bottom line
Boswellia is a legitimate knee osteoarthritis supplement candidate, especially in proprietary extracts that match the clinical trials. It is not a generic inflammation cure-all, and the best evidence should be kept tightly anchored to osteoarthritis pain and function outcomes.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Reduced knee osteoarthritis pain in some proprietary-extract trials
- Improved knee osteoarthritis function in some proprietary-extract trials
Secondary Outcomes
- Possible reduction in inflammatory markers such as hs-CRP in some studies
- Product-specific fast-onset pain relief signal in short trials
Safety
Contraindications and Interactions
Contraindications
- Pregnancy
- Lactation
- Active peptic ulcer disease or significant GI sensitivity
Side effects
- Mild GI upset
- Reflux or stomach irritation
Interactions
- Anticoagulant or antiplatelet strategies
- NSAIDs or GI-irritating supplements
Avoid if
- You are using it for a vague systemic-inflammation goal instead of a defined osteoarthritis target
- You cannot verify the extract identity or standardization
- Pregnancy or lactation without clinician guidance
Evidence
Study-level References
bs-SRC-001Systematic review and meta-analysis
Sourceopen_in_newDalmonte T, Andreani G, Rudelli C, Isani G. Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis. A systematic review and meta-analysis. Phytother Res. 2024;38(12):5672-5689. doi:10.1002/ptr.8336. PMID:39314013.
Population: Adults with clinician-diagnosed knee osteoarthritis enrolled in randomized controlled trials of Boswellia oleogum resin extracts.
Dose protocol: Various Boswellia extract protocols across knee osteoarthritis trials
Key findings: Overall pooled effects were heterogeneous, but placebo subgroup analyses supported a beneficial WOMAC signal.
Notes: Best current overview and the right anchor for confidence calibration.
Paper content
This 2024 meta-analysis is the best current anchor for Boswellia use framing in knee osteoarthritis. The pooled result was weakened by high heterogeneity, but subgroup analyses against placebo were more favorable. The main practical conclusion is that Boswellia has a legitimate osteoarthritis evidence base, but it is driven by varied proprietary extracts and should not be generalized into a broad anti-inflammatory cure-all claim.
bs-SRC-002Randomized placebo-controlled trial
Sourceopen_in_newKumar B et al. A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study. J Am Nutr Assoc. 2025;44(5):375-386. doi:10.1080/27697061.2024.2438894. PMID:39700461.
Population: Adults with Kellgren-Lawrence grade II to III knee osteoarthritis
Dose protocol: 100 mg/day of standardized Boswellia extract for 180 days
Key findings: Six-month randomized placebo-controlled data showed better pain, function, walking performance, and MRI cartilage morphology versus placebo.
Notes: Strong modern trial, but still tied to one proprietary extract.
Paper content
In an 80-person 180-day randomized placebo-controlled study, 100 mg/day of a standardized Boswellia serrata extract improved pain, function, walking performance, and MRI cartilage morphology in adults with mild to moderate knee osteoarthritis. Biomarkers linked to inflammation and cartilage degradation also fell versus placebo, but the trial remained product specific.
bs-SRC-003Randomized controlled trial
Sourceopen_in_newKarlapudi V, Sunkara KB, Konda PR, et al. Efficacy and Safety of Aflapin, a Novel Boswellia Serrata Extract, in the Treatment of Osteoarthritis of the Knee. A short-term 30-day randomized, double-blind, placebo-controlled clinical study. J Am Nutr Assoc. 2023;42(2):159-168. doi:10.1080/07315724.2021.2014370. PMID:35512759.
Population: Adults with knee osteoarthritis meeting American College of Rheumatology-based inclusion criteria.
Dose protocol: 100 mg daily for 30 days
Key findings: Improved VAS, Lequesne, and WOMAC outcomes, with pain relief reported as early as day 5.
Notes: Strong short-term RCT, but proprietary and short.
Paper content
This placebo-controlled trial supports a meaningful short-term symptom benefit for a proprietary Boswellia extract in knee osteoarthritis. The rapid onset is attractive, but the study used one branded formulation and a short 30-day window, so the results should be interpreted as product-specific rather than as proof that all Boswellia supplements work the same way.
bs-SRC-004Randomized controlled trial
Sourceopen_in_newSengupta K, Krishnaraju AV, Vishal AA, et al. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;33(5):1457-1468. doi:10.1002/ptr.6338. PMID:30838706.
Population: Adults with osteoarthritis of the knee.
Dose protocol: 169.33 mg twice daily for 120 days
Key findings: Improved pain, stiffness, function, walking ability, hs-CRP, and some radiographic measures versus placebo.
Notes: Useful longer-duration trial, but industry affiliated and product specific.
Paper content
This longer-duration placebo-controlled trial supports Boswellia as a plausible osteoarthritis symptom supplement, with improvements in pain, stiffness, physical function, and hs-CRP over 120 days. It is useful because it runs longer than many early Boswellia studies, but it remains tied to a branded extract and includes industry-affiliated authors.
bs-SRC-005Systematic review and network meta-analysis.
Sourceopen_in_newInprasit C, Bunyamahote N, Boonpattharatthiti P, Thimkorn P, Intakhiao P, Dhippayom T. Evaluating the efficacy and safety of Curcuma longa, Boswellia serrata, and their mixed formulation in treating knee osteoarthritis. Complement Ther Med. 2026;96:103256. doi:10.1016/j.ctim.2025.103256. PMID:41082950.
Population: Adults with knee osteoarthritis across 20 randomized controlled trials.
Dose protocol: Various Boswellia extract protocols across 20 knee OA RCTs
Key findings: Network meta-analysis found modified Boswellia formulations significantly improved WOMAC pain, stiffness, and function compared to other groups.
Notes: Adds network-level comparative ranking evidence for Boswellia in OA.
Paper content
This network meta-analysis pooled 20 RCTs (1633 participants) comparing Curcuma longa, Boswellia serrata, and their combined formulations for knee osteoarthritis. Modified Boswellia formulations showed significant improvements in WOMAC pain, stiffness, and knee function compared to other treatment groups. No significant safety differences emerged between herbal interventions and placebo. The analysis supports Boswellia as a potentially effective botanical for OA symptom management, with modified formulations performing particularly well. The network approach is useful for comparative ranking but limited by heterogeneity in extract types and trial quality across included studies.
bs-SRC-006Randomized double-blind multicenter placebo-controlled clinical trial
Sourceopen_in_newVaidya N, Agarwal R, Dipankar DG, Patkar H, Ganu G, Nagore D, Godse C, Mehta A, Mehta D, Nair S. Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-blind, Multicenter, Placebo-Controlled Clinical Trial. Pharm Res. 2025;42(2):249-269. doi:10.1007/s11095-025-03818-2. PMID:39875757.
Population: Adults with knee osteoarthritis.
Dose protocol: Boswellia serrata 300 mg plus Apium graveolens seed extract 250 mg daily for 90 days
Key findings: Improved pain, stiffness, swelling, and cartilage-related biomarkers over 90 days without an adverse-event signal.
Notes: Combination product, so it strengthens Boswellia-centered OA evidence but does not isolate Boswellia monotherapy.
Paper content
This 90-day multicenter randomized trial evaluated a Boswellia serrata plus celery-seed nutraceutical in 62 adults with knee osteoarthritis. The intervention improved pain and function outcomes and shifted inflammatory and cartilage-turnover biomarkers in a favorable direction versus placebo, without apparent safety problems on laboratory or ECG evaluation. Because the product combines Boswellia with Apium graveolens, it supports Boswellia-centered osteoarthritis use while still limiting claims about generic Boswellia monotherapy.